Transcatheter Aortic Valve Replacement is Cost Effective Compared With Surgical Replacement for Low-Risk Patients

An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and low surgical risk, found that despite higher procedural costs, at 2-year follow-up, quality-adjusted life expectancy was greater and total costs were lower with TAVR; as a result, at 2-years, TAVR was cost-effective for these patients.

Intermediate-Risk Patients Have Similar Five-Year Outcomes With Transcatheter Or Surgical Aortic Valve Replacement

New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality or stroke between patients at intermediate surgical risk who had transcatheter aortic valve replacement (TAVR) or surgery. Although there were initially more reinterventions after TAVR, the rates were similar after two years and key clinical endpoints were also similar.

Edoxaban May Be Effective Treatment for Atrial Fibrillation After Transcatheter Aortic Valve Replacement

Mount Sinai study is first to compare this anticoagulant with the standard of care in large randomized clinical trial

Late-Breaking Science Announced for TVT 2021

The Cardiovascular Research Foundation (CRF) announced that TVT 2021 will feature 12 studies as Late-Breaking Clinical Science. An annual meeting from CRF, TVT features cutting-edge research and techniques for structural heart interventions. TVT will take place online and in person, with limited attendance, at the Fontainebleau Miami Beach in Miami Beach, Florida July 20-22, 2021.

TVT 2021 Program Now Available

The program for TVT 2021: The Structural Heart Summit is now available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions. TVT will take place online and in person, with limited attendance, at the Fontainebleau Miami Beach in Miami Beach, Florida July 20-22, 2021.

Mount Sinai Cardiovascular Doctors to Receive Honors During American College of Cardiology 70th Annual Scientific Session

William Whang, MD, Associate Professor of Medicine (Cardiology), and Gilbert Tang, MD, MSc, MBA, Associate Professor of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai, are receiving the 2021 Simon Dack Awards for their exceptional contributions to the Journal of the American College of Cardiology (JACC).

Morristown Medical Center Among 1st to Receive American College of Cardiology Transcatheter Valve Certification

Atlantic Health System’s Morristown Medical Center has received American College of Cardiology (ACC) Transcatheter Valve Certification, a designation of excellence that recognizes demonstrated expertise and commitment in treating patients undergoing transcatheter valve repair and replacement procedures, including transcatheter aortic valve replacement (TAVR).

Morristown Medical Center’s Dr. Philippe Généreux Again Named One of World’s Most Highly Cited Researchers

For the second year, Philippe Géneréux, MD, Co-Director of the Structural Heart Program at Atlantic Health System’s Morristown Medical Center and an interventional cardiologist internationally known for his novel research, has been named a Highly Cited Researcher by the Clarivate™ Web of Science™ Group. Dr. Géneréux is the only New Jersey-based physician-scientist to be named to this year’s list in the Clinical Medicine category. Clinical Medicine requires more highly cited papers than any other field to meet the criteria for inclusion on the Highly Cited list.

Free Access to TCT Connect Extended for One Year

All educational programming from TCT Connect will be available to registrants for free through October 18, 2021. TCT is the annual scientific symposium of the Cardiovascular Research Foundation (CRF) and the world’s premier educational meeting specializing in interventional cardiovascular medicine.

Trial Finds that Interventional Closure of Residual Atrial Septal Defect One-Month Post Transcatheter Mitral Valve Repair Was Not Superior to Medical Treatment

The MITHRAS randomized clinical trial found that interventional closure of an iatrogenic atrial septal defect (iASD) driven by transcatheter mitral valve repair (TMVR) was not superior to conservative medical treatment with regard to the primary endpoint of change in six-minute walking distance.

TCT Connect Agenda Now Available

The TCT Connect agenda is now available online. TCT, the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place online October 14-18. Every year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the globe to present and discuss the latest evidence-based research in the field.

Announcing the TCT Connect Late-Breaking Trials and Science

The Cardiovascular Research Foundation (CRF) has announced over 30 late-breaking trial and science presentations that will be reported at TCT Connect. TCT, the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place online October 14-18.

Baylor Scott & White Health Again Recognized as Most Awarded Not-for-profit Health System in Texas by U.S. News & World Report

In the midst of the extraordinary health challenge presented by the COVID-19 pandemic, Baylor Scott & White Health remains committed to quality, safe care and helping Texas communities navigate the uncertainty of the SARS-CoV-2 virus. Today, this commitment to safety and quality is recognized as U.S. News & World Report releases its 2020-2021 Best Hospitals list.

Late-Breaking Science Announced for TVT Connect

The Cardiovascular Research Foundation (CRF) announced that TVT Connect will feature eight studies as Late-Breaking Clinical Science. They will be presented during episodes moderated by the editors of Circulation: Cardiovascular Interventions and JACC: Cardiovascular Interventions. Each late-breaking science episode will host a live wrap-up and Q&A session afterwards.

NEJM: Transcatheter Aortic Valve Replacement Shows Similar Safety Outcomes as Open-Heart Surgery

A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic-valve replacement (TAVR), had similar key 5-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve. The study appears on the New England Journal of Medicine site.

Young Age Does Not Equal Low Risk for Patients Needing Aortic Valve Replacement

While transcatheter aortic valve replacement (TAVR) continues to expand its pool of eligible patients, open heart surgery—resulting in excellent patient survival and fewer strokes when compared to TAVR—is the best option for young and middle-aged adults with aortic valve disease—at least for now.

More Heart Valve Patients May Choose Minimally Invasive Procedure

Since August, when the FDA approved a minimally invasive heart valve procedure for an expanded group of patients with aortic stenosis, many more patients are opting for the procedure known as transcatheter aortic valve replacement (TAVR). With this latest approval, the procedure can now be performed on a wide spectrum of patients, from patients too sick to undergo open-heart surgery to those who would be considered low risk for open-heart surgery.

New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis

The Portico IDE study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems available in the United States.

New Five-Year Data Shows Similar Outcomes for TAVR and SAVR in Patients with Severe Aortic Stenosis and Intermediate Surgical Risk

Five-year results from the PARTNER 2A trial found that patients with severe aortic stenosis (AS) and intermediate surgical risk who underwent transcatheter aortic valve replacement (TAVR) had similar rates of death and disabling stroke compared to those who had surgical aortic valve replacement (SAVR). However, TAVR using a transthoracic approach had poorer outcomes compared to SAVR.